Filing Flows › Celldex Therapeutics (CLDX) › Q2 2026 › vs Q1 2026
Celldex Therapeutics (CLDX) Q2 2026 vs Q1 2026 (quarter over quarter)
Celldex Therapeutics's revenue rose $7K (+47%) from $15K in Q1 2026 to $22K in Q2 2026.
Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year), net loss $73.5M, operating cash flow −$57.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $22K | $15K | $7K | +47% |
| Other income, net | $7.1M | $5.8M | $1.4M | +24% |
| Net loss | $73.5M | $78.7M | −$5.2M | -7% |
| Costs & expenses | $80.6M | $84.5M | −$3.8M | -5% |
| Operating costs | $80.6M | $84.5M | −$3.8M | -5% |
| Research & development | $67.5M | $73.0M | −$5.5M | -7% |
| General & admin | $13.1M | $11.4M | $1.7M | +14% |
| Operating cash sources | $73.5M | $78.7M | −$5.2M | -7% |
| Depreciation & amortization | $902K | $854K | $48K | +6% |
| Share-based compensation | $8.4M | $8.5M | −$115K | -1% |
| Working capital & other | $6.8M | $3.7M | $3.1M | +82% |
| Cash used in operations | $57.4M | $65.6M | −$8.2M | -12% |
| Net loss absorbed | $73.5M | $78.7M | −$5.2M | -7% |
Questions
How much did Celldex Therapeutics's revenue grow quarter over quarter in Q2 2026?
Celldex Therapeutics's revenue rose $7K (+47%) from $15K in Q1 2026 to $22K in Q2 2026.